Likuiditas cepet citiusonc.com (CTOR)

The daily price chart for Citius Oncology, Inc. (CTOR) on the GURU.Markets platform currently shows 0.35. Current revenues are generated by the market launch of a cutaneous lymphoma treatment, although promotion costs remain significant. The brand is valued in the medical community for developing precise methods to combat leukemias. Financial success relies on insurance reimbursements for bladder cancer therapy.

For Citius Oncology, Inc. (CTOR), a developer of innovative blood cancer treatments, the quick ratio serves as an indicator of financial autonomy. This metric assesses the company's ability to meet short-term obligations using its most liquid assets. The calculation excludes slow-moving inventories, focusing exclusively on cash and accounts receivable. A stable level of this ratio ensures the uninterrupted funding of costly oncology research without the risk of cash flow gaps.